Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2022 Current vs New Patch Formulations in Healthy Volunteers
NCT02042729Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of donepezil transdermal patch in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Adverse Events at 40 days and Frequency of Adverse Events at 40 days. Started Aug 2012; status: completed.
02
Drugs
donepezil transdermal patch
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02042729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042729.